Epiomic Epidemiology Series: Angina Pectoris Forecast in 20 Major Markets 2018–2028

July 2018 | 68 pages | ID: ED7C1502625EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Angina Pectoris in 20 Major Markets

Angina Pectoris (AP) is the term given to the pain or discomfort felt when the heart muscle lacks an adequate supply of oxygen rich blood (ischaemia). The main cause of angina is coronary arterial disease (CAD), which is the obstruction of coronary arteries due to build up of atherosclerotic plaque. Other forms of angina include microvascular angina (MVD) also known as Cardiac Syndrome X.

This report provides the current prevalent population for AP across 20 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of course of progression, coronary vessels affected and associated co-morbidities of AP. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, patient parameters and co-morbidities of AP have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AP include:

• Diabetes
• Hypertension
• Dyslipidaemia
• Chronic heart failure
• Peripheral artery disease
• Erectile dysfunction
• Aortic valve sclerosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global AP market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of AP and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding on the impact of specific co-morbid conditions on the prevalent population of AP patients.
• Identification of AP patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of AP patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR ANGINA PECTORIS

FEATURES OF ANGINA PECTORIS PATIENTS

ANGINA PECTORIS PATIENTS WITH CORONARY ARTERY DISEASE

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Canadian Cardiovascular Society (CCS) classification scale of angina pectoris
Table 2. Prevalence of angina pectoris, total (000s)
Table 3. Prevalence of angina pectoris, males (000s)
Table 4. Prevalence of angina pectoris, females (000s)
Table 5. Patients with angina pectoris by severity (CCS), total (000s)
Table 6. Patients with angina pectoris by BMI status, total (000s)
Table 7. Angina pectoris patients with coronary artery disease by type, total (000s)
Table 8. Patients with angina pectoris by CAC score, total (000s)
Table 9. Abbreviations and acronyms used in the report
Table 10. USA prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 11. USA prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 12. Canada prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 13. Canada prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 14. France prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 15. France prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 16. Germany prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 17. Germany prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 18. Italy prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 19. Italy prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 20. Spain prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 21. Spain prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 22. UK prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 23. UK prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 24. Poland prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 25. Poland prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 26. Netherlands prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 27. Netherlands prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 28. Ireland prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 29. Ireland prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 30. Russia prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 31. Russia prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 32. Turkey prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 33. Turkey prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 34. Japan prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 35. Japan prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 36. China prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 37. China prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 38. South Korea prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 39. South Korea prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 40. India prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 41. India prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 42. Australia prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 43. Australia prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 44. Brazil prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 45. Brazil prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 46. Mexico prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 47. Mexico prevalence of angina pectoris by 5-yr age cohort, females (000s)
Table 48. Argentina prevalence of angina pectoris by 5-yr age cohort, males (000s)
Table 49. Argentina prevalence of angina pectoris by 5-yr age cohort, females (000s)